The FDA has classified a recall of dexmedetomidine hydrochloride in 0.9% sodium chloride injection, 400 micrograms per 100 mL (4 micrograms/mL) in the Galaxy 100 mL single-dose container, from Baxter Healthcare Corporation, as Class II. The stated reason is deviations from current good manufacturing practice, and the recall status is recorded as ongoing.
Read the classification carefully, because the two halves say different things. Class II is the middle tier: use of the product may cause temporary or medically reversible adverse health consequences, and the probability of serious harm is remote. CGMP deviations are a process failure at the plant, not a finding that patients have been hurt — there is no safety signal attached to this record, no report of an adverse event, and no statement about what the deviation was.
So the problem this creates in your unit is logistical. Premixed dexmedetomidine bags are what most ICUs and theatres reach for precisely because they remove a dilution step, and a recall of one presentation means either a substitute presentation or a return to compounding from concentrate. That substitution is where the actual risk sits: the concentrate is 100 micrograms/mL and the premix 4 micrograms/mL, a twenty-five-fold difference, and unit staff accustomed to hanging a bag will be handling vials. Check lot numbers against the recall notice, tell pharmacy before you run out rather than after, and if you revert to compounding, put a second check on the dilution.
- Check your stock's lot numbers against the FDA recall notice rather than assuming your bags are unaffected.
- Tell pharmacy and ICU stock control now — substitution decisions are better made before a shortage bites.
- If you revert to compounding from 100 micrograms/mL concentrate, add an independent double-check of the dilution.
- Label compounded syringes and bags with concentration in micrograms/mL, not just the drug name.
- Do not tell families a product has been recalled for a safety problem — this one has not.
Why it matters
The risk in a recall like this is created by what replaces the product, not by the product itself.
Don't overread it
A CGMP deviation is a manufacturing process finding, not evidence that any patient has been harmed.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for anaesthesiology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free